Breakthrough in Genetic Disorder Treatment: GC Pharma’s Sanfilippo Syndrome Drug Receives FDA Phase 1 Approval

Sanfilippo,GC Pharma,Regulatory,Treatment,Regulatory

Sanfilippo Syndrome, also known as Mucopolysaccharidosis Type III, is a rare genetic disorder caused by the body’s inability to produce an enzyme necessary for breaking down heparan sulfate. This accumulation leads to severe organ damage and developmental delays. GC Pharma, in collaboration with biotech firm Nobel Pharma, has announced that their innovative treatment for Sanfilippo … 더 읽기

Meet the Pioneers Redefining the Space Industry: Join the SpaceK 2024 Forum in Seoul

Space,SpaceK 2024,korea,healthcare

On June 5th, Chosun Biz, the economic media arm of the Chosun Media Group, will host the inaugural SpaceK 2024 forum at the Korean Federation of Science and Technology Societies in Gangnam, Seoul. This event aims to highlight the visionary minds driving the new era of space exploration and commercialization, known as NewSpace. SpaceK 2024 … 더 읽기

The Importance of Early Retinal Screening for Newborns: Preventing Childhood Blindness

Retinal,Diseases,Yejoon,Advocacy,Congenital

Congenital retinal diseases, such as Familial Exudative Vitreoretinopathy (FEVR), are conditions that can lead to severe vision impairment or even blindness in newborns. These diseases are often undetectable without specific screening, such as the retinal screening (fundus examination) that is not commonly included in standard neonatal check-ups. A poignant example is the case of Yejoon, … 더 읽기